Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202501167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Jayasingha Arachchige Chathuranga Chanaka Jayasingha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, NF-kappa B, Signal Transduction, Anti-Inflammatory Agents. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Sakuranin (SKR) is naturally occurring compound known for its anti‐inflammatory and antioxidant activities; however, its precise molecular mechanisms in modulating inflammation through toll‐like receptor 4 (TLR4) signaling remain unclear. This study investigates the anti‐inflammatory effects of SKR in lipopolysaccharide (LPS)‐stimulated RAW 264.7 macrophages and zebrafish larvae, focusing on the TLR4–nuclear factor‐kappa B (NF‐κB) signaling pathway. SKR significantly inhibited the production of nitric oxide (NO), prostaglandin E 2 (PGE 2 ), interleukin‐12 (IL‐12), and tumor necrosis factor‐alpha (TNF‐α), while downregulating the expression of inducible NO synthase (NOS2) and cyclooxygenase‐2 (COX2) at both transcriptional and translational levels. In vivo, SKR reduced LPS‐induced mortality, restored cardiac function, and attenuated immune cell infiltration in zebrafish larvae, further underscoring its systemic anti‐inflammatory effects. Mechanistic studies revealed that SKR inhibited NF‐κB nuclear translocation and directly interacted with the TLR4/myeloid differentiation factor 2 (MD2) complex, thereby disrupting LPS–TLR4 signaling. Molecular docking and colocalization analyses confirmed that SKR directly binds TLR4, potentially interfering with LPS recognition and downstream pro‐inflammatory signaling activation. Collectively, these findings highlight SKR as a potent modulator of TLR4‐mediated inflammation, offering promising therapeutic potential for inflammatory disorders. Further investigations into its pharmacokinetics, bioavailability, and long‐term efficacy in chronic inflammatory conditions are warranted to support its clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea.
- Forest Microbiology and Application Division, National Institute of Forest Science, Suwon, Republic of Korea.
- Key Laboratory of Advanced Technology for Drug Preparation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
- Department of Biochemistry, College of Korean Medicine, Dong-Eui University, Busan, Republic of Korea.
- Biological Resources Research Department, Nakdonggang National Institute of Biological Resources, Sangju, Republic of Korea.
ORCID-Profile: Gi-Young Kim
Zitieren
APA
Jayasingha, J. A. C. C., Lee, K. T., Jin, C. Y., Choi, Y. H., Lee, C. S., & Kim, G. Y. (2025). Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202501167
Vancouver
Jayasingha JACC, Lee KT, Jin CY, Choi YH, Lee CS, Kim GY. Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202501167
BibTeX
@article{Jayasingha2025,
author = {Jayasingha, Jayasingha Arachchige Chathuranga Chanaka and Lee, Kyoung Tae and Jin, Cheng-Yun and Choi, Yung Hyun and Lee, Chang Soo and Kim, Gi-Young},
title = {Sakuranin Is a Novel Anti‐Inflammatory Agent Targeting TLR4–NF‐κB Signaling Pathways},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202501167}
}
EUVIMED